KEYNOTE SPEAKER:

BART OATES, Esq.
Former Center for the New York Giants and San Francisco 49ers.
Currently, the co-founder and General Counsel
All-Pro Title Group, LLC

Bart graduated from Brigham Young University in 1983 and in addition to being an All-American he also won the Cougar Club's Memorial Scholarship Award as a junior. Before he signed with the Giants, he also won 2 championships with the USFL.

Bart is co-founder and General Counsel to All-Pro Title Group, LLC. which has been providing quality and comprehensive title service to lawyers and lenders in New Jersey and New York.

PANELISTS:

DAVID BALTO
Senior Fellow
Center For American Progress

David Balto is a Senior Fellow at American Progress focusing on competition policy, intellectual property law, and health care. He has over 20 years of experience as an antitrust attorney in the private sector, the Antitrust Division of the Department of Justice, and the Federal Trade Commission. He is nationally known for his expertise in competition policy in high tech industries, semiconductors, health care, pharmaceuticals, medical devices, media, and financial services. He regularly provides advice on mergers, strategic alliances, and joint ventures.

From 1995-2001 he was the policy director of the Bureau of Competition of the Federal Trade Commission and attorney advisor to Chairman Robert Pitofsky. In these leadership roles Mr. Balto was a senior advisor in developing competition policy and identifying key enforcement initiatives. He helped draft guidelines involving intellectual property, joint ventures, and health care. He played a key role in several litigated cases, including the challenges to the Staples/Office Depot and Heinz/Beechnut mergers, the Intel monopolization case, and the challenges to anticompetitive conduct by several pharmaceutical companies. He is the only person to twice win the FTC's award for outstanding scholarship and won the FTC's award for distinguished service, the highest award given a staff attorney.

Mr. Balto has authored more than 60 articles about competition policy focusing on intellectual property, health care, pharmaceuticals, financial services, and mergers. He regularly testifies before Congress, state legislatures, the FTC, and DOJ. He has authored numerous amicus briefs for consumer groups in seminal antitrust cases.

ADAM BERGER
Managing Director, Head of M&A
Leerink Swann

Adam Berger is a Managing Director and Head of Mergers and Acquisitions at Leerink Swann. Immediately prior to joining Leerink Swann, Mr. Berger was a Managing Director and Head of Healthcare Mergers and Acquisitions for Citigroup Global Markets, having been with the firm since 1991 when he joined Salomon Brothers. During his 19 year M&A career, Mr. Berger has advised on over 125 transactions totaling nearly $400 billion in value. He holds a B.S. and B.A. from The Wharton School and the University of Pennsylvania, where he graduated Phi Beta Kappa and Magna Cum Laude.

SUSAN BERSON
Senior Member, Health Law Practice
Mintz Levin

Susan is Managing Member of the firm's Washington, D.C. office. She returned to Mintz Levin after a two year hiatus during which she served as General Counsel, Public and Senior Markets Group of UnitedHealth Group, a Fortune 20 company and one of the nation's leading managed care organizations. In her role, Susan was responsible for the legal and regulatory oversight of United's government programs (including Medicare and Medicaid) and was also the chief legal counsel for all pharmacy services. Susan successfully established a strategically-organized legal and regulatory affairs team that included a first-rate litigation and risk management team, a robust audit management team and a national compliance team, each dedicated to addressing the many needs of government-sponsored programs. Prior to her experience at UnitedHealth Group, Susan practiced as a member at Mintz Levin for six years, where she was the head of the Health Law practice, and prior to that practiced in New York for many years.

As a member of the Health Law practice, Susan focuses on advising private and public health care service providers, including those in the managed care, device, diagnostic and pharmaceutical sectors, often in the context of affiliation and service agreements, including some of the nation's largest pharmacy service agreements, mergers, acquisitions, joint ventures and network development. She also advises venture capital groups and investment banks on the investment in health related businesses.

With a representation that focuses on a broad spectrum of state and federal regulatory laws unique to the health care industry, and the application of such laws to the structuring and execution of complex business arrangements, Susan regularly advises health care clients on such issues as federal and state anti-kickback and self-referral laws, emerging developments in health care legislation, privacy, including compliance with HIPAA, state regulatory issues such as corporate practice of medicine and fee-splitting prohibitions, the negotiation of managed care arrangements and service contracts with providers and facilities and the development, implementation and enforcement of compliance programs. Some of Susan's recent work includes the structuring and negotiation of mergers and acquisitions involving government programs, the negotiation of rebate and pharmacy benefit service contracts, both in the commercial, Medicaid and Part D context, the structuring of disease management and other managed care programs, the structuring of incentive payment arrangements and the negotiation of service and network contracts for a variety of health care related companies.

Susan practiced in New York for many years prior to moving to Washington. She is a Phi Beta Kappa, magna cum laude graduate of the University of Rochester, and she received her J.D. from Columbia University School of Law, where she was a Harlan Fiske Stone Scholar.

PATRICK CLINTON
Editor-in-Chief 
Pharmaceutical Executive

DAVID CUMMINGS
Managing Partner
Agile Equity

David Cummings has been a co-founding Managing Partner of Agile Equity since 1998. Mr. Cummings is responsible for the strategic development and continued expansion of the firm's investment banking business, including sourcing and executing both domestic and International transactions in IT services, software and healthcare industries. Mr. Cummings has over eighteen years of corporate finance experience through a diverse background in mergers and acquisitions, equity and debt financing activities. Mr. Cummings has successfully completed over one-hundred M&A transaction with several billion dollars of enterprise value for both privately held and large multinational public companies. In addition, he has authored numerous corporate finance articles for various professional journals, magazines and periodicals. Previously, Mr. Cummings spent seven years as a Vice President and Officer with Fleet Financial Group where he developed acquisition and divestiture strategies that contributed to the banks growth. Mr. Cummings began his career with State Street Research & Management as an equity analyst specializing in software technology. Mr. Cummings has a Bachelors of Sciences Degree in Business Administration and Management and is a graduate of New York University, Stern School of Business.

ARON DANTZIG
Managing Director, Co-Head and Co-Founder
Fortress Investments Drawbridge Special Opportunities Fund's Healthcare Group

Aron Dantzig is a Managing Director and Co-Head and Co-Founder of Fortress Investment's Drawbridge Special Opportunities Fund's Health Care Group. Prior to joining Fortress, Aron spent the majority of his career with Lehman Brothers in New York, where he worked in the Leveraged Finance Group structuring a variety of bank and bond transactions in conjunction with the firm's investment banking clients. Mr. Dantzig started his career with GE Capital's Merchant Banking Group, providing senior debt and mezzanine acquisition financing in support of financial sponsors operating in the the middle market. Aron earned his Juris Doctorate and Masters of Business Administration from Case Western Reserve University and holds a BS in Finance from The Ohio State University.

TODD DAVIS
Co-founder and Managing Director
Cowen Healthcare Royalty Partners

Mr. Davis is a founder, Managing Director and a member of the CHRP Investment Committee. Previously, Mr. Davis was a partner at Paul Capital Partners, where he focused on making royalty-related investments for the Paul Royalty Funds and was responsible for U.S. sourcing. Prior to that, Mr. Davis was a partner at Apax Partners, responsible for making private equity investments in biopharmaceutical companies. Mr. Davis has extensive healthcare operating experience, having worked in business development and general management at Elan Pharmaceuticals and in sales and marketing at Abbott Laboratories. Mr. Davis has led or facilitated healthcare investments totaling over $365 million, of which approximately $200 million were direct equity investments. Mr. Davis currently serves on the board of Ligand Pharmaceuticals and historically has served on the boards of several private and public companies including Verus Pharmaceuticals, Prism Pharmaceuticals, Prometheus Laboratories and SkinMedica. He is a former U.S. naval officer and holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard Business School.

BENJAMIN EDMANDS
Managing Director
CCMP Capital Advisors, LLP

Benjamin Edmands is a Managing Director in the New York office of CCMP Capital. Mr. Edmands focuses on making investments in the healthcare sector and has been responsible for CCMP's investments in CareMore Medical Enterprises, Hanger, DJ Orthopedics, MedQuest Associates, Warner Chilcott and Legacy Hospital Partners. He holds a B.A. from Colgate University and an M.B.A. from Columbia Business School. Prior to joining CCMP in 1993, Mr. Edmands worked in Chemical Bank's Investment Banking Group and Structured Finance Group. Mr. Edmands currently serves on the board of directors of CareMore Medical Enterprises, National Surgical Care and Legacy Hospital Partners.

CCMP Capital Advisors, LLC, is a leading global private equity firm specializing in buyouts and growth equity investments in companies ranging from $500 million to more than $3 billion in size. CCMP Capital's founders have invested over $12 billion since 1984 in five primary industries: Consumer, Retail and Services; Energy; Healthcare Infrastructure; Industrials; and Media and Telecom. Selected investments include: Aramark Corporation, Edwards Limited, Generac Power Systems, Grupo Corporativo ONO, Hanley Wood, Legacy Hospital Partners, Quiznos Sub and Warner Chilcott. CCMP Capital's latest fund, CCMP Capital Investors II, L.P., closed in September 2007 with commitments of $3.4 billion.

CCMP Capital has offices in New York, Houston and London. Through active management, its global resources and its powerful value creation model, CCMP Capital has established a reputation as a world-class investment partner.

STEVEN ELEK III
Partner, Healthcare Transaction Services Leader
PricewaterhouseCoopers

Steven Elek, Partner, leads the Healthcare Practice in the Transaction Services Group of PricewaterhouseCoopers LLP. He is responsible for delivering a wide range of merger, acquisition, divestiture and corporate finance related services. Steve has over twenty-five years experience in a wide range of healthcare industry sectors that give him a broad understanding of the interrelationships amongst the sectors. His sector experience includes health insurance/managed care, general acute-care hospitals, psychiatric hospitals, integrated delivery systems, long-term care, rehabilitation centers, home care, clinical laboratories, medical device manufacturers, and pharmaceutical companies.

Steve is an attorney and a Certified Public Accountant. He is a past President of the Association for Corporate Growth's Philadelphia Chapter and a past Chairman of its Board of Directors. He is a member of the HealthCare Financial Management Association, American Institute of Certified Public Accountants, Pennsylvania Institute of Certified Public Accountants, the Pennsylvania Bar Association and the Philadelphia Bar Association. Steve has been a frequent speaker and author on various acquisition, divestiture and financing topics.

DR. CRAIG FRANCES
Managing Director
Summit Partners

Craig Frances, M.D. is a Managing Director in the Palo Alto office of Summit Partners, a private equity and venture capital firm that has raised more than $11 billion since inception. He leads healthcare investing on the West Coast. Craig's recent investments include National Veterinary Associates, the largest private owner of free-standing veterinary hospitals in the United States; HealthCare Partners, the largest private physician group in California; and Physicians Formula, the largest and fastest growing, independent cosmetics manufacturer in the mass market.

Prior to Summit, Craig was President of The .tv Corporation Int'l, acquired by Verisign (NASDAQ: VRSN); co-founder of yourPharmacy.com, a leading online pharmacy backed by Express Scripts; and co-founder of Expert Consensus Guidelines.

Craig was Chief Medical Resident at the University of California, San Francisco and Valedictorian at Cornell Medical College. Craig's board directorships and investments currently include HealthCare Partners and National Veterinary Associates. He previously held board or advisory posts with Commission Junction, HealthAllies, Medscape, and Physicians Formula.

CHRIS GARABEDIAN
Vice President of Corporate Strategy
Celgene Corporation

Chris Garabedian is currently Vice President of Corporate Strategy for Celgene Corporation, a leading international bipharmaceutical company.

Chris has a career that spans 15 years across the pharmaceutical and biotechnology industries.  At Celgene, Chris is responsible for helping shape the company's overall corporate strategy, including its long-term financial plan, portfolio prioritization, and assessing transformational M&A opportunities. Prior to joining Celgene, Chris served in global leadership positions at Gilead Sciences as VP of Corporate Development, VP of Marketing, and VP of Medical Affairs and helped the company grow from a market value of less than $1 billion to its current status as a leader in the biotechnology industry.

Chris also served in roles at Abbott Laboratories, COR Therapeutics, and Migliara/Kaplan Associates, a consulting firm to the pharmaceutical/biotech industries.

Chris has a B.S. in Marketing from the University of Maryland and has spoken on the biotechnology industry at Berkeley's Haas School of Business and Columbia University Business School.

BUDDY GUMINA
Partner, Head of U.S. Healthcare
Apax Partners LP

Buddy Gumina is a Partner and Head of US Healthcare at Apax Partners. He focuses on investments in healthcare services, products, pharma and healthcare IT. Some recent deals have included Trizetto, Inc.; Qualitest Pharmaceuticals; Spectrum Laboratory Network; Encompass Home Health; Voyager HospiceCare, Inc.; and MagnaCare Holdings, Inc.

Prior to joining Apax Partners, Buddy was a Partner at Saunders Karp & Megrue, where he specialized in investments in healthcare and business services. Before joining Saunders Karp & Megrue, Buddy was an Associate at DLJ Merchant Banking Partners where he focused on healthcare services and business services. Prior to that, he was an Analyst in the High Yield Group of Kidder, Peabody & Co. where he specialized in public and private debt financings and recapitalizations.

Buddy received an MBA from the Harvard Graduate School of Business Administration and a BA in Political Science from Yale University.

DR. JOHN G. HUNTER
Vice Chairman of the Department of Surgery and Chief of Plastic Surgery, New York Methodist Hospital and Clinical Associate Professor of Surgery
Weill Cornell Medical College

John G. Hunter, MD, MMM is Vice Chairman of the Department of Surgery and Chief of Plastic Surgery at New York Methodist Hospital, and Clinical Associate Professor of Surgery at Weill Cornell Medical College. Dr. Hunter serves as Special Adviser to the President for Patient Safety Initiatives of the American Association for Accreditation of Ambulatory Surgery Facilities, Inc., and is a Commander in the U.S. Navy Medical Corps. Dr. Hunter's academic interests are national healthcare policy, patient safety, and surgical quality improvement.

Dr. Hunter is a graduate of Fordham University and SUNY Downstate Medical Center College of Medicine. He received a Master of Medical Management degree from Carnegie Mellon University. Dr. Hunter is a past president of the New York Regional Society of Plastic Surgeons, and past chairman of the New York Academy of Medicine Section of Plastic Surgery.

PATRICK HURST
Managing Director
Houlihan Lokey

Mr. Hurst is the National Director of the Healthcare Investment Banking Group and a Managing Director in the Chicago office of Houlihan Lokey.

Mr. Hurst has managed a wide variety of corporate finance and financial restructuring engagements in the healthcare industry. Mr. Hurst has been involved in numerous transactions involving nursing homes, hospitals, managed care companies, home care agencies and other healthcare providers as well as medical product manufacturers. Mr. Hurst is also involved in the firm's investment banking activities including private placements of debt and equity capital and structuring shareholder liquidity and other recapitalization transactions. Prior to joining Houlihan Lokey he worked in the Consulting Group of Ernst & Young as well as a national consulting firm. Mr. Hurst is a frequent speaker on subjects of mergers and acquisitions, financing and restructurings in the healthcare industry. Mr. Hurst earned his B.A. in Business Administration from Marquette University and an M.B.A. in Finance from the University of Wisconsin-Madison and he is licensed with the NASD as a Registered General Securities Representative (Series #7, #24, #63).

SAMUEL D. ISALY
Founder and Managing Partner
OrbiMed Advisors

Samuel D. Isaly is a founder and the Managing Partner of OrbiMed. Mr. Isaly is one of the world's most recognized healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Mr. Isaly has been a pharmaceutical analyst with Merrill Lynch, Legg Mason and SoGen Swiss International. In 1982, Mr. Isaly founded Gramercy Associates, a boutique pharmaceutical research firm that analyzed the world's 100 leading pharmaceutical companies. In 1986, S.G. Warburg acquired Gramercy Associates and Mr. Isaly became Senior Vice President and Head of Worldwide Pharmaceutical Research. Mr. Isaly created OrbiMed's asset management business in 1989 through OrbiMed's predecessor organization, Mehta and Isaly. Mr. Isaly has a B.A. in Economics from Princeton University and a M. Sc. (Econ.) from The London School of Economics.

CHRISTOPHER KERSEY
Managing Member, Partner
Camden Partners

Chris is a Partner and joined Camden Partners in 2008. Chris has over 11 years of investing, operating and clinical experience in the health care and life science industries. Prior to joining Camden Partners, he served as a Managing Director of Cogene Ventures, at the time the largest health care and life science late-stage venture capital fund in the Southern United States. Chris began his career as an Associate at the venerable Menlo Ventures where he focused on health care and life science investments.

Chris gained operational experience as the Chief Business Development Officer and Chief Medical Officer of RediClinic LLC, one of the nation's largest independent operators of retail-based medical clinics. His clinical research background includes fellowships at the National Institutes of Health (NIH) and the Emory University School of Medicine, where he focused on molecular biology and cardiovascular surgery, respectively.

Chris has served in a variety of community, civic and professional organizations, including as President of the Houston Private Equity Association and Board Director of the Memorial Hermann Healthcare System Foundation.

Chris received his B.A. degree from Stanford University, his M.B.A. degree from the Harvard Business School and his M.D. degree from the Emory University School of Medicine.

STEPHEN KRUPA
Managing Member
Psilos Group

Stephen Krupa founded Psilos with Dr. Albert S. Waxman andLisa Suennen in 1998 and heads Psilos' East Coast Office. Mr. Krupa focuses primarily on identifyinginvestment opportunities in next generation healthcare services and healthcare information technologycompanies. In addition, he advises many of Psilos' portfolio companies in the areas of capital formation and merger and acquisition strategy and structure. Mr. Krupa has served on several Psilosportfolio company boards, including Active Health Management (exited) and HealthScribe (exited). Mr. Krupacurrently serves on the Board of Directors of Caregiver Services, Click4Care, Comprehensive NeuroScience, Extend Health and HealthEdge Software.

Prior to Psilos, Mr. Krupa was a Vice President of Wasserstein Perella & Co., a leadinginternational investment bank. During his time at Wasserstein, Mr. Krupa specialized in public and private mergersand acquisitions advisory work, much of which was focused in the healthcare industry. Mr. Krupa's work atWasserstein resulted in the consummation of strategic transactions with an aggregate market value of over $11.0 billion. Previously, Mr. Krupa was an associate in the investment banking department of Kidder Peabody & Co. From 1987 to 1992, Mr. Krupa worked first as a mechanical engineer and software applications developer and then as a manager of new businessdevelopment for Johnson Controls, Inc., a leading manufacturer of process controls systems. Mr. Krupa holds an M.B.A. with Distinction from the Wharton School of the University of Pennsylvania, where he graduated a Palmer Scholar; and a B.S. in Mechanical Engineering from the University of South Florida where he was elected to Tau Beta Pi.

ALEX LASH
Senior Writer
The Deal LLC

Alex Lash covers the biopharmaceutical industry and other healthcare related topics for The Deal, with a focus on biotech venture activity, licensing deals and M&A. He particularly enjoys covering emerging areas of biomedical science such as stem-cell research, RNA interference, next-generation proteins and biodefense--along with the business and finance models that grow around them. Lash joined the Deal in 2004.

As a founding staff member of CNET's News.com, Lash covered high technology issues including the rise and fall of Netscape, the first browser company, and the antitrust case against Microsoft. He helped launch The Industry Standard as a reporter covering Microsoft and its competitors.

Lash has also written for a wide range of publications, including Wired, Architecture, ReadyMade, PC World, Chow, Business 2.0 and In Formation. He lives in San Francisco with his wife and daughter.

DR. ANNARIE LYLES
Senior Vice President, Head of Business Development
Genmab, Inc.

Dr. Annarie Lyles is SVP and Head of Business Development with Genmab, a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. She joined Genmab in 2005 and has nearly two decades of experience in biology-related businesses. Through her prior business development post with Medarex, Inc, she gained a broad knowledge of antibody therapeutics. She has authored several dozen scientific publications, served as Adjunct Associate Professor at Columbia University, and was on the Governing Board of Princeton University's Graduate Alumni Association. Dr. Lyles earned undergraduate and graduate biology degrees from Yale and Princeton Universities.

SAMUEL MAIZEL
Partner
Pachulski Stang Ziehl & Jones LLP

Mr. Maizel's practice includes bankruptcy matters and financial restructuring in and out of court, with a focus on the healthcare industry. He has also served as lead bankruptcy counsel to debtors in chapter 11 cases, as an examiner appointed pursuant to the request of the Securities and Exchange Commission, and as lead counsel to various official bankruptcy committees and to individual creditors. He has led the firm's representation of the Attorneys General of forty-six states and six territories (Settling States) that are parties to the Master Settlement Agreement with the tobacco industry since 2000. Before joining the firm, he represented the federal government in bankruptcy, district, and appellate courts nationwide as a trial attorney in the US Department of Justice's Commercial Litigation Branch. He has also served in US Army's The Judge Advocate General's Corps, including service in Operation Desert Shield/Desert Storm, for which he was awarded the Bronze Star Medal. Previously he served as an Infantry Officer in the 101st Airborne Division and the 3rd US Infantry Regiment (The Old Guard). He has lectured extensively, is widely published, and been interviewed on television and radio on bankruptcy topics. In 2007, he was named a 'Super Lawyer' in a region-wide peer survey, a honor bestowed on only 5% of Southern California attorneys, and holds an AV Peer Rating, Martindale-Hubbell's highest peer recognition for ethical standards and legal ability. Mr. Maizel is a resident in the Los Angeles office.

RICHARD L. MANNING
Director, Transactions Services Strategy Group
PricewaterhouseCoopers

Richard Manning, PhD Economics, is a Director in the Healthcare, Pharmaceuticals & Life Sciences team based in New York. Richard leads engagements in commercial due diligence as well as various growth and innovation strategy projects. In both academic and business settings, he has more than 18 years experience leading teams and undertaking analyses of strategic and business environment problems, evaluating biopharmaceutical product portfolios, assisting clients in business model change, and assessing the economic impact of various health care innovations.

Specifically, he has recently led analyses of potential acquisition targets for corporate and private equity clients, co-led a team developing a novel diagnostics business model for a major innovator in the health care sector, and has led major team efforts assessing the economic and social contribution of the biopharmaceutical industry to several key states in the US; a large scale research project forecasting of the impact advances in health care on the well being of US and other developed country populations; and an assessment of the financial impact and strategy options facing a large health care company associated with likely changes in the government and private health-insurance options available to Americans.

Prior to joining the PwC Biopharmaceuticals and Life Sciences Strategy team in August 2008, Richard spent 11 years at Pfizer, the world's largest biopharmaceutical company, in various leadership positions focused on the economics of the innovative pharmaceutical industry, strategic issues and transformational change in health care, regulation and the overall business and public policy environment. His work has influenced thinking and strategic initiatives widely across the company. Most recently he was the Senior Director of Economic and Policy Research.

Previous to joining Pfizer in 1997, Richard was an economics professor at Brigham Young University and a visiting professor at the University of Chicago Graduate School of Business. He has been an active researcher and thought leader in the biopharmaceutical and healthcare industries and in public policy. He maintains a wide network of contacts among top level academics in business and economics and has authored and co-authored numerous peer reviewed and other articles on economics, strategy, policy, and the biopharmaceuticals industry. He is a frequent speaker on these issues in conferences, private meetings and as a guest lecturer at major universities.

Richard received both master's and Ph.D. degrees from the department of economics at the University of Chicago where he studied under several Nobel prizing winning economists, co-authored papers and books with them and focused on research related to industrial organization, economic analysis of law and the economics of government regulation. He graduated magna cum laude in economics with a minor in mathematics from Brigham Young University.

OLIVER MARTI
Managing Director/Portfolio Manager Healthcare
Columbus Circle Investors

Mr. Marti joined Columbus Circle Investors in November, 1999. Prior to this, he was the Senior Healthcare Analyst with Pequot Capital Management. Mr. Marti previously worked as a Healthcare Equity Research Analyst at Morgan Stanley. Mr. Marti started his career on Wall Street as an Analyst in Morgan Stanley's Investment Banking Group. Mr. Marti graduated in three years from Brown University Summa Cum Laude with a double major in Economics and Business Management.

WILLIAM MCCONNELL
Washington D.C. Bureau Chief
The Deal LLC

Bill McConnell has been the Washington D.C. bureau chief for The Deal LLC since August 2005.

Before joining The Deal, he was the Washington D.C. correspondent for Broadcasting & Cable, where he spent seven years reporting on the debate over media ownership, the Federal Communications Commission's crackdown on broadcast indecency and the rollout of digital television. Previously, McConnell was a reporter for American Banker, covering Capitol Hill and banking regulators. He also worked at The Daily Record in Baltimore, tracking Maryland's public companies, the state's biotech industry and the Baltimore advertising industry.

He began his career at The Daily Times in Maryville, Tenn.

McConnell earned a master's in economic communication from American University in Washington D.C. and a bachelor's degree in journalism from the University of Tennessee.

MICHAEL NEUBERGER
Managing Director and Global Head of Healthcare Investment Banking
Jefferies & Co.

Michael Neuberger is a Managing Director and Global Head of Jefferies Healthcare Investment Banking Group. Jefferies Healthcare Investment Banking Group covers all segments within the industry including Biotechnology, Specialty Pharmaceuticals, Pharmaceutical Services, HCIT, Healthcare Services and Medical Devices. Recent clients include Hologic, Inverness Medical Innovations, Talyst, Hill-Rom and Cynosure. Prior to joining Jefferies in 2004, Michael was a Managing Director at SG Cowen & Co. where he was Head of the Medical Device and HCIT Investment Banking Practice. Prior to SG Cowen, Mr. Neuberger was formerly a Managing Director at Smith Barney in the Healthcare Investment Banking Group and worked at Kidder, Peabody as a senior member of the firm's Healthcare Group. He began his Investment Banking career in the M&A Department at Lehman Brothers. In addition to Investment Banking, Mr. Neuberger also spent approximately two years as President and a Director of a venture - backed healthcare start up. Mr. Neuberger received an MBA from the Columbia Business School and a BA from Boston College.

KEITH PAGNANI
Partner
Sullivan Cromwell

Keith Pagnani is actively involved in the Firm's corporate practice and has broad experience in merger and acquisition transactions for a range of domestic and international clients.

Mr. Pagnani is a frequent speaker on M&A and corporate matters, including as a member of the Practising Law Institute. He was a panelist for "It's a Hostile World: Creating and Implementing Takeover Defenses" at PLI's Doing Deals 2008: Understanding the Nuts and Bolts of Transactional Practice and on "The Role of Buyout Funds in Leading Canadian Deals" at ALM's The US/Canadian Cross-Border M&A Forum.

Mr. Pagnani also is actively involved in the Firm's management and administration, including as co-head of the Firm's Healthcare and Life Sciences practice and as a member of the Firm's Administrative and Diversity Committees.

Mr. Pagnani is named as a leading lawyer for M&A in New York Super Lawyers (2008, 2007, 2006), for banking and finance, intellectual property, M&A and private equity in The Lawdragon 500: New Stars, New Worlds (2006), and as a leading lawyer finalist in The Lawdragon 500: Leading Lawyers in America (2007).

TOM PERKINS
Senior Vice President, Corporate Development
Quintiles Transnational Corp.-NovaQuest

Tom heads the day-to-day operations of the NovaQuest group of Quintiles. NovaQuest leads Quintiles' partnering strategy, including: (i) risk-based investments in the commercialization and clinical development of pharmaceutical products; and (ii) long-term "strategic resourcing" partnerships focused on productivity benefits. Prior to his Corporate Development appointment, Tom served as General Counsel of the group since its inception in August 2000, and also served as the Deputy General Counsel for Quintiles Transnational Corp. Tom joined Quintiles in 1996 to provide legal support for Quintiles' Corporate Development, strategic alliance and global contracting activities. Prior to Quintiles, Tom served as Assistant General Counsel for Coastal Healthcare Group. Tom also worked for five years with the large Texas law firm of Haynes and Boone in its corporate finance group. Tom earned his bachelor's degree in business administration from Southern Methodist University and earned his juris doctor from the University of Texas at Austin

DR. ARCHIE ROBERTS
Founder
Living Heart Foundation - CHN Network

FIONA SCHAEFFER
Partner
Weil, Gotshal & Manges LLP

Fiona Schaeffer is a partner at Weil, Gotshal & Manges with expertise in a broad range of antitrust counseling, litigation and transactional matters. She advises leading companies in an array of industries, with particular expertise in the healthcare, financial services and media sectors. She has represented major corporations in complex antitrust litigations, including multi-district treble damages class actions as well as private suits in federal and state courts. She also has expertise in EU competition law and has appeared before the European Courts (ECJ and CFI) and the European Commission and has represented clients in investigations and proceedings in a number of EU member states. She advises private equity and industrial clients on mergers & acquisitions, joint ventures and other combinations and coordinates antitrust approvals for multinational transactions in the US, EU and other jurisdictions worldwide. In an increasingly global economy, her international experience brings added value to clients who conduct business internationally and interact with different legal systems and regulators.

Ms. Schaeffer has written and lectured on numerous antitrust subjects in the US and EU. She is a vice chair of the International Antitrust Committee of the ABA's Section of Antitrust Law. She is also a co-chair of the International Antitrust Committee of the ABA's Section of International Law and is a past editor of the Committee's annual Year in Review which comprises a summary of key developments (legislation, conduct and merger cases) in numerous jurisdictions worldwide, published in The International Lawyer.

Ms. Schaeffer was recognized in Chambers USA - America's Leading Lawyers for Business 2005, 2006, 2007 and 2008 as a leading antitrust lawyer, and was included in the Guide to the World's Leading Competition and Antitrust Lawyers 2008.

Ms. Schaeffer is also a member of the Executive Committee of the Antitrust Section of the New York State Bar Association and a past member of the Antitrust & Trade Regulation Committee of the Association of the City Bar of New York in which she also served as liaison to the International Competition Network (ICN).

Recent merger cases she has successfully completed include Houghton Mifflin Riverdeep Group plc's acquisition of the Harcourt Education business of Reed Elsevier Group plc and UnitedHealth Group Incorporated's acquisition of PacifiCare Health System. Recent litigations include representing T.H. Lee in a putative nationwide antitrust class action including the leading U.S. private equity firms and representing MasterCard International Incorporated in a multi-district federal and state class action lawsuit (In Re Currency Conversion Fee Antitrust Litigation) and related state actions.

University of Adelaide (LL.B., 1992); University of Adelaide (B.Econ., 1992); University of Oxford (B.C.L., 1994).

RICHARD H. STOWE
General Partner
Health Enterprise Partners

Mr. Stowe joined HEP after serving as a Senior Advisor to CB Health Ventures since 2000. He has been active in the private equity business since 1970, and was a General Partner of Welsh, Carson, Anderson & Stowe from April 1979, shortly after the firm's formation, until December 1998. From 1999 until 2005, Mr. Stowe was also a Senior Advisor to Capital Counsel, LLC, a firm managing approximately $1.0 billion in marketable securities. From 1970 to 1979, Mr. Stowe was a principal of New Court Securities Corporation (now Rothschild Inc.), a large venture capital firm at the time. From 1965 to 1967 Mr. Stowe was a Systems Engineer at IBM Corporation.

Mr. Stowe is a trustee emeritus of Bowdoin College, where he served as Chairman of the Investment Committee from 2001 to 2004, and an Adjunct Trustee of Rensselaer Polytechnic Institute. He is also a member of Harvard Business School's Board of Dean's Advisors, Harvard Business School's Healthcare Initiative Advisory Board and Harvard School of Public Health's Health Policy and Management Executive Council. He is a director of HMS Holdings Corp. (NASDAQ: HMSY), Brim Holding Company, Inc. (a CBHF II company), Behavioral Centers of America Holdings LLC (a HEP company) and Chamberlin Edmonds & Associates, Inc.

Mr. Stowe holds a BSEE degree from Rensselaer Polytechnic Institute (1965) and an MBA from Harvard Business School (1970), where he was a Baker Scholar.

ROBERT TEITELMAN
Editor-in-Chief
The Deal LLC

Robert Teitelman is editor in chief of The Deal LLC. As a member of the company's Executive Committee, Teitelman is responsible for the editorial operations of The Deal's print and electronic products. Teitelman has more than 20 years experience in financial journalism.

Teitelman joined The Deal in December 1998 from Institutional Investor, where he had worked since 1989. He began as assistant managing editor and was promoted to managing editor before becoming the editor of Institutional Investor in 1997. While at Institutional Investor, Teitelman also wrote news and feature articles on companies, including American Express, Lazard Freres and Banc One, and received awards from the Deadline Club and the American Society of Business Press Editors. Teitelman also worked as a writer and editor for Forbes and Financial World. In addition, he is the author of two books, "Profits of Science: The American Marriage of Business and Technology" and "Gene Dreams: Wall Street, Academia and the Rise of Biotechnology."

Teitelman is a graduate of the College of William and Mary and Columbia University.

DR. ALBERT WAXMAN
CEO and Senior Managing Member
Psilos Group

Dr. Waxman created the vision for Psilos after a lengthy career as an entrepreneur in the healthcare field, most recently as Chairman and Chief Executive Officer of Merit Behavioral Care and its predecessor companies, American Biodyne and Medco Behavioral Care (a subsidiary of Merck Co.) until the company was acquired by Magellan Health Services in February 1998. During this period, he brought American Biodyne public, led its sale to Medco Containment Services (later acquired by Merck), organized a management buyout of it from Merck with KKR, and grew the company's revenues to over $800 million.

Prior to American Biodyne, Dr. Waxman founded and served as President, Chairman and CEO of Diasonics, Inc., one of the first medical companies to provide ultrasound and magnetic resonance imaging in the U.S. Dr. Waxman holds several U.S. and foreign patents for display, imaging and diagnostic technologies and products. He has also been instrumental in the start-up and success of several other healthcare companies throughout his career.

As a serial entrepreneur, Dr. Waxman recognized the need for the value-added venture capitalist--one who understands and can impact all facets of young company development from strategy and operations to financial and business development. Through his activities at Psilos, Dr. Waxman is chairman and/or a director of several Psilos companies including: Comprehensive NeuroScience, Inc., HealthEdge, CareGuide, Inc., Quality Metric, Extend Health and Mauna Kea. He is also on the Board of Cenegenics (a non-Psilos investment). He focuses much of his time on building relationships among Psilos companies and leading Psilos' overall investments strategy.

In addition to his current Psilos responsibilities, Dr. Waxman serves as a commissioner of Healthcare for the State of New Mexico and as President of the Center for Contemporary Arts in Santa Fe.

Dr. Waxman holds a Bachelor of Science degree in Electrical Engineering from the City College of New York and Master and Doctoral degrees in Electrical Engineering and Physics from Princeton University.

TADD WESSEL
Director
OrbiMed Advisors

Tadd S. Wessel joined OrbiMed in 2009 to focus on structured finance, fixed income, and royalty investments. Prior to joining OrbiMed, Mr. Wessel was a Vice President in the Drawbridge Special Opportunities Fund at Fortress Investment Group focused on healthcare investments. Prior to Fortress, he was a Vice President in the healthcare investment banking department of Citigroup. Mr. Wessel began his career with Robertson Stephens in San Francisco, where he worked in the life sciences investment banking group. Mr. Wessel holds a BA from Princeton University.

NATHANIEL M. ZILKHA
Director
Kohlberg Kravis Roberts & Co.

Nat Zilkha is a Director of KKR, where he focuses on investments in healthcare. Prior to joining KKR, Mr. Zilkha was a Vice President of Goldman Sachs, where he led the healthcare investing efforts for the Goldman Sachs Capital Partners funds. Over his career he has invested over $1.5 billion of equity in various sectors of healthcare including services, managed care, medical devices and pharmaceuticals. Mr. Zilkha graduated cum laude from Princeton University.

The Healthcare Dealmaking Symposium provides a unique opportunity to position yourself and/or your firm as thought leaders in the healthcare, medical device, biotechnology and drug discovery sectors in a face-to-face environment with the corporate and financial executives who will drive the deals in 2009.

To be considered for a speaking role, please send your information to:

Martha Brown
Vice President, Communications and Development
212.313.9218
mbrown@TheDeal.com